NFKB1 and neoplasm: Targeted inhibition of the NF-κB pathway using BAY11–7082 suppresses the promoting effects of IL-18 on tumor proliferation and invasion, enabling IL-18 to act as a co-stimulatory cytokine to facilitate immunotherapy.